reduce insulin dose when starting glp-1 receptor agonist Glucagon-like peptide-1 receptor agonists (GLP Glucagon-like peptide-1 receptor: mechanisms and

Journal of Endocrinology, 204

Glucagon-like peptide-1 (GLP-1) receptor agonists represent a class of medications primarily used for managing type 2 diabetes mellitus and, more recently, for chronic weight management

Risk reduction strategies may include postponement/cancellation of the procedure, ingestion of a clear fluid diet for some period of time before the nothing by mouth period, avoidance of deep sedation/general anesthesia if possible, and use of rapid-sequence induction if general anesthesia is required

Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, Simpson RW, Dear AE

Semaglutide GLP-1 (Ozempic, Wegovy) and Zepbound ( tirzepatide ) are two of the most discussed medications for weight loss, and many of our patients inquire about their long-term safety

Although these three types of cells each have distinct functions, it is more important to note that the somatostatin, glucagon, and insulin they secrete work together through mutual regulation and feedback mechanisms to maintain blood glucose balance and overall metabolic homeostasis